title: The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.
abstract: The aim of this study was to evaluate the impact of epoetin alfa (EPO) therapy on delaying progression to renal dialysis and quantify the associated medical cost savings in elderly chronic kidney disease (CKD) patients. Elderly (>/=65 years) dialysis patients who had >/=1 hemoglobin (Hb) value and >/=1 glomerular filtration rate (GFR) value of <60 mL/min/1.73 m(2) were identified using health claims and laboratory data from the period January 1999 to February 2005. Exclusion criteria included: organ transplantation, blood transfusion, use of darbepoetin alfa, and dialysis for reasons other than CKD. Each EPO patient was matched by Hb and GFR to one control patient. The time from when matched patients had the same GFR value to dialysis was compared. The economic impact of EPO on delaying dialysis was monetized using standardized health plan payments, and adjusted to 2005 United States dollars. Sixty-eight patients (34 EPO and 34 matched controls) formed the study population. The average time to dialysis was 156 days longer for the EPO group compared to the matched control group (p = 0.003). Analysis by CKD severity revealed that EPO therapy in less severe CKD patients offered a greater delay in time to dialysis (Stage 4: 213 days difference, p = 0.003; Stage 5: 104 days difference, p = 0.160). EPO treatment resulted in cost savings of $43,374-$59,222 per patient compared to non-EPO matched controls. This retrospective matched cohort study suggests that EPO therapy has a beneficial impact on delaying progression to dialysis in elderly CKD patients, especially in those with less severe CKD.
authors.affiliation: Groupe d'Analyse, Ltée, Montréal, Québec, Canada.
authors.forename: Patrick
authors.initials: P
authors.lastname: Lefebvre
authors.forename: Mei Sheng
authors.initials: MS
authors.lastname: Duh
authors.forename: Samir H
authors.initials: SH
authors.lastname: Mody
authors.forename: Brahim
authors.initials: B
authors.lastname: Bookhart
authors.forename: Catherine Tak
authors.initials: CT
authors.lastname: Piech
mesh_terms: D000368:Aged; D015897:Comorbidity; D017046:Cost Savings; D018450:Disease Progression; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000191:economics* / Q000627:therapeutic use; D005919:Glomerular Filtration Rate; D006397:Hematinics / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000191:economics / Q000473:pathology / Q000628:therapy*; D006278:Medicare; D018803:Models, Economic; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000191:economics*; D012189:Retrospective Studies; D013997:Time Factors; D014481:United States
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa